Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR4 | P46093 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3921357 | 0.88 | GPR4 (0.43) | GPR4NR1H2EPHX2GPR119SQOR | |
| SCHEMBL3919827 | 0.86 | GPR4 (0.42) | GPR4NR1H2EPHX2CHRM2CHRM4 | |
| SCHEMBL3923435 | 0.86 | GPR4 (0.41) | GPR4NR1H2EPHX2GPR119SQOR | |
| SCHEMBL3929576 | 0.80 | BRD4 (0.39) | NR1H2ATRATRIP | |
| SCHEMBL3923323 | 0.80 | BRD4 (0.43) | NR1H2ATRATRIP | |
| SCHEMBL3923334 | 0.79 | MCHR1 (0.44) | NR1H2ATRATRIP | |
| SCHEMBL3929570 | 0.77 | BRD4 (0.39) | NR1H2ATRATRIP | |
| SCHEMBL3920962 | 0.73 | NR1H2 (0.45) | NR1H2MAP2K4 | |
| SCHEMBL3921577 | 0.73 | NR1H2 (0.45) | NR1H2MAP2K4 | |
| SCHEMBL3920773 | 0.71 | NR1H2 (0.44) | NR1H2MAP2K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491710-B2 | Organophosphorus derivatives of indazoles and use thereof as medicinal products | AVENTIS PHARMA S.A. (FR) | 2009-02-17 | — | — | US | disclosed |
| US-20050137171-A1 | Novel organophosphorus derivatives of indazoles and use thereof as medicinal products | AVENTIS PHARMA S.A. (FR) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137171-A1 | Novel organophosphorus derivatives of indazoles and use thereof as medicinal products | PPIP5K2, INPPL1, IP6K3 | GPR4 2045/4885NR1H2 2030/4885EPHX2 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.